I Stock 1206790646

Governments and businesses around the world continue to respond to the rapidly evolving COVID-19 (Coronavirus) outbreak. As a leading CRO and healthcare intelligence company, PRA Health Sciences recognizes that with this leadership comes a responsibility to mobilize our resources to fight the pandemic and to mitigate any challenges that may lead to difficulties in conducting clinical trials. The safety and well-being of our patients, customers, partners, employees, and the global community is our highest priority.

Brandon Thomas
Brandon Thomas
Senior Writer

PRA’s Executive Crisis Management Team, which is comprised of senior leaders and representatives from departments throughout the organization, has been actively monitoring the global situation and managing PRA’s actions and response since the outbreak was first reported. Under the leadership of this team, PRA has implemented a number of actions and safeguards to ensure both the well-being of employees and continuity of PRA’s vital business operations around the globe.

Internally, PRA is continually providing guidance to its workforce and recommending a number of everyday preventive measures each of us can take to help prevent the spread of Coronavirus, including:

Maintain Good Personal Hygiene

  • Wash your hands often with soap and water for at least 20 seconds. Use an alcohol-based hand sanitizer that contains at least 60% alcohol if soap and water are not available.
  • Avoid touching your eyes, nose, and mouth with unwashed hands.
  • Avoid close contact with people who are sick.
  • Stay home when you are sick.
  • Cover your cough or sneeze with a tissue, then throw the tissue in the trash.
  • Clean and disinfect frequently touched objects and surfaces.

Adhere to Social Distancing

  • Be aware that in-person meetings of more than 10 people are discouraged. Instead, use technology to support the meeting of large groups.
  • Avoid contact with people who are sick.
  • Maintain social distancing of at least 1-2 meters (3-6 feet) between yourself and other people, whether they appear to be sick or not.
  • Most PRA offices are now giving employees the option to work from home and are ensuring their teams are equipped with the technology and IT support to fulfill all work responsibilities when working remotely.

Travel Suspended

PRA has restricted virtually all business travel. Only the most essential travel, such as clinical monitoring, is still permitted in some instances. The Association of Clinical Research Organizations (ACRO) has issued guidance for clinical monitoring for all of its members during the COVID-19 situation; PRA’s response aligns with ACRO’s guidance.

PRA’s employees will comply with all federal, state, and local travel restrictions, and recognize that all government public health guidelines, directives, and restrictions supersede those of PRA. Any employee returning home from travel may be asked to self-quarantine and delay returning to PRA offices or sites.

Expertise and Innovation

In collaboration with our partners, clients, and others within the industry, PRA business units and employees across the globe are working diligently to find innovative ways to lead and support the global response to the COVID-19 pandemic.

Our industry has seen a growth of wearable technologies for clinical trials in recent years. The COVID-19 outbreak highlights the importance of wearable devices, such as activity trackers and sensors, which allow patients to participate in a trial from the comfort and convenience of their own home. Through this technology, PRA is able to monitor vital signs such as heart rate, respiratory data, exercise, and movement levels as patients go about their day-to-day lives. These fully virtual studies can completely eliminate visits to sites and help reduce the overall burden patients can experience.

Learn more about PRA’s mobile clinical trial platforms and its commitment to eliminating the barriers of traditional clinical trials:

PRA has introduced newly developed, state-of-the-art digital health solutions for remote patient monitoring. These solutions will help continue clinical research, specifically in response to COVID-19.

PRA’s COVID-19 Clinical Study Support Mobile Application can virtually connect patients worldwide with clinical trial sites and health professionals from any location via their mobile device, enabling the continuance of important clinical trials.

Patients across the entire health system, either in clinical trials, in hospitals, as members of health plans, or employer groups, can also benefit from newly developed tools specific to COVID-19 for remote monitoring. These educational monitoring programs, developed by Care Innovations, a PRA Health Sciences company, deliver critical information and virtual clinical assistance for patients who are asymptomatic, exposed, or diagnosed with COVID-19.

Prepared During Challenging Times

PRA is committed to supporting the global community as we navigate these uncertain and challenging times together.

Our team of clinical research and healthcare intelligence experts are dedicated to preventing and eliminating diseases—and they are determined to lead the fight in eradicating COVID-19 and ensuring people around the world live the healthiest lives possible.

Explore related content and topics